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Background: Deflation cough (DC), i.e. the cough-like expiratory expulsive efforts evoked by maximal
lung emptying, is partially inhibited by prior intake of an antacid. We wished to compare the effects of an
anti-reflux medical device (Gastrotuss®) and of a widely used antacid drug (Maalox®) on the number of
expiratory thrusts evoked by maximal lung emptying in chronic cough patients.
Methods: Twenty consecutive chronic cough outpatients also presenting DC attended the clinic on three
separate occasions and were requested to inhale to near total lung capacity and then exhale maximally
for at least 6 s. Trained investigators detected aurally the number of cough efforts evoked by maximal
lung emptying prior to and 1, 5, 10, 30 e 60 min after administration of either Maalox®, or Gastrotuss® or
placebo. The liking of the administered agents was also rated.
Results: In control conditions, maximal lung emptying was consistently accompanied by the appearance
of DC. The number of efforts was unchanged after placebo whereas it was markedly (P < 0.001) reduced 1
e10 min following Maalox® and Gastrotuss® administration. The value of liking for Gastrotuss® was
greater (P < 0.01) than those of Maalox® and placebo.
Conclusions: Pre-treatment with anti-reflux agents with a substantially different composition are equally
effective in inhibiting DC. The liking of the two compounds used in the present experiments differed
considerably and may be important to improve adherence to treatment in patients undergoing long-term
therapy for reflux-related symptoms.
© 2015 Published by Elsevier Ltd.1. Introduction
Recently, we have observed that during maximal lung emptying
some patients with chronic cough and symptoms of gastro-
oesophageal reflux produce one or more cough efforts that typi-
cally occur when lung volume is emptied to near residual volume
[1,2]. The mechanism underlying this phenomenon, termed
“deflation cough” (DC), appears to depend upon oesophageal
acidification, since in the majority of patients DC is markedly
reduced or even abolished by pre-treatment with a 40-ml Maalox®
(Novartis International AG, Basel, CH), a solution containing
aluminium hydroxide (3.25 g/100 ml) and magnesium hydroxideesophageal reflux.
ntal and Clinical Medicine,
055 7947516; fax: þ39 055
tana).(3.65 g/100 ml) [1]. The hydroxides react with excess acid in the
stomach, reducing its acidity [3,4]; the agent is commonly pre-
scribed as an antacid to minimise the clinical symptoms of oeso-
phageal acidification in patients with gastro-oesophageal reflux
(GOR) [5] and its inhibitory action on DC was shown to be signifi-
cantly stronger than that of placebo [1]. Gastrotuss® (Drugs Mineral
and Generics, Pomezia, Rome, I) is a liquid preparation, registered
as a medical device, largely employed in the control symptoms of
GOR, including chronic cough [6]. The device is an association of
different agents including simethicon e an anti-foaming agent that
decreases the surface tension of gas bubbles e and magnesium
alginate, i.e. the magnesium salt of alginic acid which is adminis-
tered orally in the treatment of GOR [6]. After ingestion, the device
combineswith gastric acid to form a viscous gel, which floats on top
of the gastric contents and acts as a physical barrier to reflux [6].
However, the effectiveness of Gastrotuss® in the control of DC has
not been assessed. Thus, the primary objective of the study was to
assess the effectiveness of Gastrotuss® in preventing or reducing DC
E. Chellini et al. / Pulmonary Pharmacology & Therapeutics 33 (2015) 11e1412in a group of outpatients with chronic cough. The secondary
objective of the study was to compare the effectiveness ofMaalox®
and Gastrotuss® in the control of DC and to assess whether patients
show any preferences regarding the liking of the agents employed.
2. Materials and methods
2.1. Patients
We recruited 20 consecutive outpatients (13 females, Table 1)
with chronic cough of any origin and DC who attended the Cough
Centre at the Azienda Ospedaliero Universitaria Careggi, Florence,
Italy. Patients were non-smokers or ex-smokers (n ¼ 6) for longer
than 24 months, none of them reported recent (<4 weeks) airway
infections. Patients were requested to be off any acid-suppressing
therapy for at least 1 week before enrollment in the study. All
procedures were in accordance with the Helsinki Declaration and
the study was approved by the local Institutional Review Board (n.
869/13); patients gave their signed informed consent to participate.
2.2. Treatments
Maalox® (40 ml), or Gastrotuss® (40 ml) or placebo, i.e. a solution
freshly prepared with 30 ml mineral water, 10 ml UHT milk and 10
drops of a multivitamin compound [1], were employed. A single
dose of the active agents or placebo was randomly administered at
each scheduled visit. The sequence of administered treatments was
allocated according to an on-line randomization web site (www.
randomization.com).
2.3. Study design and protocol
This was a randomized, placebo-controlled, double blind, cross-
over study. Blindness was guaranteed by the fact that all treatments
were administered by indistinguishable syringes into the patient's
mouth, the identity of which were blinded to patients and in-
vestigators. Patients attended the clinic on three occasions sepa-
rated by a time interval of 48e72 h. Food intake was withheld 3 h
prior to each study day. At the clinic, patients underwent a general
clinical assessment and the assessment of DC as described in theTable 1
Patients' anthropometric, functional and clinical characteristics.
Pt. no. Sex Age (years) BMI FEV1/FVC Cough duration (mon
1 M 55 29.07 80 72
2 F 59 21.36 75 96
3 F 51 20.81 79 12
4 M 23 19.59 77 24
5 F 57 25.40 79 12
6 M 67 31.25 81 11
7 F 40 22.59 73 60
8 F 70 25.39 79 24
9 F 66 23.83 77 10
10 M 62 25.26 72 36
11 M 37 24.38 79 9
12 F 67 29.64 77 10
13 M 55 25.10 86 8
14 F 29 24.50 80 9
15 F 61 27.18 81 12
16 M 60 27.12 77 84
17 F 65 28.09 73 72
18 F 68 25.71 79 7
19 F 50 25.10 81 100
20 F 70 24.91 74 96
Mean e 55.60 26.79 77.95 38.20
SD 13.65 3.23 3.39 35.35
BMI, body mass index; FEV1, forced expiratory volume at 1 s; FVC, forced vital capaci
muscarinic antagonist; Pt, patient; PPI, proton pump inhibitors.literature [1]. In brief, patients inhaled to near total lung capacity
and then exhaled slowly down to near residual volume. During the
manoeuvre patients wore a nose clip and breathed freely through a
mouthpiece to prevent pursing of the lips, a phenomenon that in
our experience may affect the appearance of DC. Patients were
trained to exhale maximally as in an attempt at emptying out the
lung as much as possible for at least 6 s. Trained investigators
detected aurally the number of cough efforts evoked by maximal
lung emptying prior to (i. e., at baseline) and 1, 5, 10, 30 e 60 min
after each treatment and noted for subsequent analyses. At base-
line, the manoeuvre was repeated 3e5 times, and a 5 min recovery
period was allowed between each expiratory effort. After comple-
tion of each trial, patients were requested to rate the liking of the
administered agent according to amethod described previously [7].
In brief, patients rated the taste using a 10 cm long visual analogue
scale. The extremes of the scale were classified from 0 (extremely
poor) to 10 (excellent).
2.4. Data analysis
Based on the results of a previous investigation [1], the sample size
was chosen to design the study to have a 80% statistical power of
detecting a 50% reduction in baseline DC frequency with the use of
one-way repeated measure analysis of variance (ANOVA) and a sig-
nificance level of 0.05. All expulsive efforts recorded during each
maximal expirationwere considered. Deflation cough frequency was
taken as the number of expiratory efforts recorded during each
maximal expiration. The number of DC events recorded at baseline
was pooled and averaged for subsequent calculations. Comparisons
between DC frequencies recorded at baseline and after placebo,
Maalox®, and Gastrotuss® administration were performed by two-
way, nonparametric, repeated-measure ANOVA followed by post-
hoc tests. Treatments (i. e. Gastrotuss®, Maalox® and placebo) and
the time intervals after administrationof eachdrugwere factors in the
ANOVA. This statistical analysis allowed us to investigate, for each
subject, interactions between drugs and the time course after their
administration. Ratings of anti-refluxagents' taste obtained at the end
of each trial were compared by one-way ANOVA followed by Dunn's
multiple comparisons test. All reported values are means ± standard
deviations (SD); a P value <0.05 was taken as significant.ths) Most prominent associated symptoms Ongoing treatment
Regurgitation PPI
Dyspnoea, dysphonia, heartburn regurgitation LAMA, PPI
Dysphonia, indigestion None
Heartburn, indigestion None
Dysphonia, regurgitation, thoracic pain None
Dysphonia, indigestion None
Dyspnoea, indigestion, regurgitation PPI
Dysphonia, dyspnoea, regurgitation ICS, PPI
Dysphonia, heartburn PPI
Heartburn, indigestion, regurgitation None
Dysphonia, heartburn PPI
Dysphonia dyspnea, indigestion None
Dysphonia, heartburn None
Heartburn, regurgitation None
Dyspnoea, heartburn LAMA, PPI
Heartburn, regurgitation None
Dysphonia, dyspnoea, regurgitation PPI, LABA, ICS
Heartburn, thoracic pain PPI
Heartburn, indigestion, regurgitation PPI, prokinetics
Dyspnoea, heartburn, thoracic pain ICS, LABA, PPI
ty; ICS, inhaled corticosteroids; LABA, long-acting b2 agonists; LAMA, long-acting
Fig. 2. Mean (SD) scores of visual analogue scale (VAS) rating the liking of Gastrotuss®
(empty column), Maalox® (grey column) or placebo (black column); *, P < 0.01 for
Gastrotuss® compared to the other agents.
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In control conditions, maximal lung emptying was consistently
accompanied by the appearance of DC in all patients examined. The
time course of mean changes in DC frequency following adminis-
tration of all study agents is depicted in Fig. 1. The mean (±SD)
number of deflation coughs recorded in control condition was
6.35 ± 1.79. This value was unchanged 1 min following placebo
(6.00 ± 1.24), whereas it was markedly (P < 0.001) reduced to
3.4 ± 1.29 and 2.07 ± 1.411 min followingMaalox® and Gastrotuss®
administration, respectively. It should be noted that placebo,
although ineffective in the patients as a group, actually reduced DC
frequency in four of them. It was, however, completely ineffective
in 16 patients. Conversely, 1 min after Maalox® administration, DC
was abolished in 13 patients and its frequency was reduced in 7 of
them. Following Gastrotuss®, DC was completely abolished in 12
patients and its frequency was reduced in 8. The reduction in DC
frequency persisted for as long as 10 min with both Maalox® and
Gastrotuss®; as a rule, values of DC frequency resumed their control
value 30 min following anti-reflux agents administration (Fig. 1).
Although the reduction in mean DC frequency after Maalox®, and
Gastrotuss® was significantly greater than with placebo (P al-
ways<0.001), no difference was found between the magnitude of
mean DC inhibition with Maalox® and that with Gastrotuss®. Pa-
tients in whom DC was only partially inhibited by the active agents
had clinical characteristics similar to those in whom antacid
administration was fully effective in abolishing deflation cough. As
a rule, patients who displayed a weaker DC inhibition to one of the
active agents, also failed to respond fully to the other (data not
shown).
As shown in Fig. 2, the mean (±SD) value of liking was
5.73 ± 1.48 for Gastrotuss®, 3.82 ± 1.48 forMaalox®, and 4.55 ± 1.60
for placebo. Between group analysis demonstrated higher
(P < 0.01) liking for Gastrotuss® compared with both Maalox® and
placebo, whereas the latter two agents reached comparable liking
scores.4. Discussion
The present findings firstly confirm our previous observation
that, in patients with chronic cough and DC, pre-treatment with
high dose of an antacid drug or a reflux-preventing medical device
significantly inhibits DC [1]. Secondly, they also confirm that DC
inhibition by these agents is of variable degree, ranging from
complete abolition of DC in some patients to a slight DC reductionFig. 1. Time course of mean (SD) changes in deflation cough (DC) frequencies observed
following administration of Gastrotuss® (empty circles) Maalox® (filled circles), or
placebo (triangles). C, control condition. The asterisks indicate the time points at which
we detected a significant (P < 0.01) difference in DC frequency between Maalox® and
Gastrotuss® compared to placebo.in others [1]. Third, the results demonstrate for the first time that an
anti-reflux medical device or an antacid drug with a substantially
different composition and mechanism of action are equally effec-
tive in inhibiting DC. Last, but not least, the results also show that
the liking of the two compounds used in the present experiments
differs considerably.
We have enrolled patients with chronic cough of any origin and
DC as assessed at the first clinical evaluation. Since the primary
purpose of the study was to evaluate the effectiveness of an anti-
reflux medical device or an antacid drugs in controlling the DC,
we were not interested in any additional recruitment criterion nor
in performing a full clinical workup to establish a diagnosis of the
chronic cough at the time of the first visit. However, since DC has
been shown to be inhibited by high dose of antacid pre-treatment
in both the present and in previous experiments [1], it can be
inferred that the pathophysiological mechanisms responsible for
chronic cough in patients examined here likely included GOR.
The pathophysiology of DC remains to be fully elucidated [1,2].
Although the chemical composition of the two products studied
varies considerably (see above), their effectiveness in controlling
DC appears to be remarkably similar, suggesting comparable pro-
tective effect against the stimuli that are involved in DC mediation
at the oesophageal level. A detailed discussion on the mechanisms
by which these products prevent DC would be beyond the scope of
this study. Both Maalox® and Gastrotuss® have been shown to
reduce on acid reflux and total acid exposure due to local chemical
Hþ- and pepsin-binding capacity [4]; in addition, due to the pres-
ence of simethicone, Gastrotuss® may also improve gastric disten-
sion with synergistic reduction of transient lower oesophageal
sphincter relaxation [6]. Since both of them seem to counteract the
effects of gastric refluxate on the oesophageal mucosa [3], it seems
plausible to infer that the mechanism of DC inhibition by these
agents involves the blocking of reflex responses of oesophageal
origin.
Most over-the-counter antitussive liquid preparations are sweet
and viscous due to added sweeteners, such as glucose, sucrose and
honey [8]. Sweeteners are usually listed as excipients, presumably
used for flavour; they impart a pleasant taste and also could mask
unpleasant tastes of other ingredients, because sweetness tends to
suppress bitterness [8]. Interestingly, sweetened preparations have
significant antitussive effects even when they contain no drugs
[9].The fact that honey has been used for thousands of years as a
cough remedy is consistent with this idea. It is unclear whether
sweetness per se is responsible for the relief that sweet prepara-
tions provide, but one study has shown that rinsing themouthwith
sucrose and inhaling menthol vapour significantly increased cough
thresholds to capsaicin [10]. Both Maalox® and Gastrotuss® contain
sweeteners and flavourings as excipients; therefore we cannot rule
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observed in the present study. Further studies are required to
investigate the effects of sweeteners preparation lacking of phar-
macologically active ingredients on the genesis of DC.
Although the role of oesophageal acidification appears to be
prominent in most instances, it seems worth recalling that in some
patients the DC is only slightly diminished by prior intake of an
antacid [1]. Of note, patients who displayed a weak response to one
of the products, also did so in response to the other one, suggesting
that failure to markedly suppress the DC is independent of the type
or composition of the agent, but rather points to the possibility that
additional mechanisms other than oesophageal acidification are
implicated in genesis of DC in these patients. In this connection, it
has been proposed [2] that the DC represents a positive feed-back
reflex response also implicating sensory nerve terminals and
afferent fibres in the lungs that are activated by the changes in
intra-thoracic caused by maximal lung emptying [11]. With DC, a
voluntary maximal deflation of the lungs to residual volume aug-
ments (paradoxically) the existing expiratory drive with further
brief expiratory efforts (the DC) [2]. Additional investigations are
required to further clarify the role of sensory signals of pulmonary
origin in the mediation of DC.
Various liquid anti-reflux or antacid agents such as those
employed here are available both as over-the-counter or prescrip-
tion medications for the treatment of GOR, peptic ulcer disease and
other ill-defined causes of dyspepsia [12]. According to published
guidelines [13], antacids or anti-reflux products are also widely
employed in the control of GOR symptoms, including chronic
chough. A possible drawback of antacid therapy is the need of
frequents drug administration, since the duration of action of these
compounds is generally short lasting [14]. On the other hand, the
need of frequents administration is known to negatively impact on
patient compliance to the therapy, especially when the liking of the
compound is low. A patient may be more likely to choose an anti-
reflux treatment if it is effective and palatable, particularly if the
taste of the agent is pleasant [7]. We have shown that, when taken
over short period of time to control DC in our experimental con-
ditions, the liking of Gastrotuss® was significantly higher than that
ofMaalox®. In consequence, it seems logical to assume that a highly
palatable anti-reflux medical device such as Gastrotuss® may be
advantageous in the long term treatment of patients with reflux-
related symptoms.
5. Conclusions
We have shown that DC can effectively be controlled by high
dose of an anti-reflux medical device or an antacid drug, a findingthat reinforces the role of oesophageal acidification in the genesis
of DC. However, the results provide additional evidence that other
mechanisms, most likely of bronchopulmonary origin also
contribute, at least in a subset of patients. The organoleptic char-
acteristics of anti-reflux/antacid products may be important to
improve adherence to treatment in patients undergoing long-term
therapy for reflux-related symptoms.
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